In-depth biotech analysis articles

In Depth 24 Jan 2024

A new chapter in cell therapy: engineered B cells reach the clinic for the first time

Cell therapy has drastically improved the scope of treatment for a number of diseases in the last few years. Now, engineered B cells are the latest approach in the field of cell therapy, having recently made it into clinical trials. But what exactly are B cells and how can they be engineered to treat diseases? […]

January 24, 2024 - 7 minutesmins - By Willow Shah-Neville

In Depth 19 Jan 2024

Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?

Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases.

January 19, 2024 - 9 minutesmins - By Willow Shah-Neville

In Depth 18 Jan 2024

GLP-1 agonists: what’s the hype about?

GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs.

January 18, 2024 - 7 minutesmins - By Roohi Mariam Peter

In Depth 17 Jan 2024

Bladder cancer treatment: where are we standing?

Bladder cancer is the 10th most common cancer. Delve into the most promising strides in bladder cancer treatment.

January 17, 2024 - 8 minutesmins - By Jules Adam

In Depth 10 Jan 2024

The biggest private biotech investments in December 2023

The companies Tome Biosciences, Bicara Therapeutics, and Seismic Therapeutic bagged the biggest biotech investments in December 2023. Around the world, food, immunology, oncology, central nervous system (CNS), and biofermentation players attracted the biggest funding rounds overall. Although December is generally a quiet time for biotech fundraising, there were still some big rounds raised in the […]

January 10, 2024 - 3 minutesmins - By Willow Shah-Neville

In Depth 4 Jan 2024

Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?

Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.

January 4, 2024 - 6 minutesmins - By Roohi Mariam Peter

In Depth 11 Dec 2023

European patents in biotech: how to prevent invalid patents?

The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process is complex but essential. As […]

December 11, 2023 - 10 minutesmins - By Jules Adam

In Depth 7 Dec 2023

The biggest private biotech investments in November 2023

The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […]

December 7, 2023 - 3 minutesmins - By Willow Shah-Neville

In Depth 30 Nov 2023

Could an Alzheimer’s vaccine make treatment more affordable?

Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]

November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter

In Depth 27 Nov 2023

How are R&D Tax Incentives shaping Australia’s biotech future?

Research and development (R&D) stands as a cornerstone for driving innovation, particularly within the biotech industry. The pivotal role of R&D extends beyond immediate commercial implications and encompasses a broader spectrum of societal and economic benefits. R&D represents significant expense, and if big companies can afford the risk, it may not be the case for […]

November 27, 2023 - 5 minutesmins - By Jules Adam

In Depth 23 Nov 2023

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments. Navigating the labyrinth: immunotherapy’s […]

November 23, 2023 - 5 minutesmins - By Jules Adam

Geographic atrophy treatment: Apellis' Syfovre vs. Astellas' Izervay.

In Depth 22 Nov 2023

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]

November 22, 2023 - 8 minutesmins - By Willow Shah-Neville

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

In Depth

A new chapter in cell therapy: engineered B cells reach the clinic for the first time

Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?

GLP-1 agonists: what’s the hype about?

Bladder cancer treatment: where are we standing?

The biggest private biotech investments in December 2023

Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?

European patents in biotech: how to prevent invalid patents?

The biggest private biotech investments in November 2023

Could an Alzheimer’s vaccine make treatment more affordable?

How are R&D Tax Incentives shaping Australia’s biotech future?

The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!